The first priority of Mitsubishi Tanabe Pharma America, Inc. (MTPA) has always been the health and safety of our community. As we continue to navigate the evolving COVID-19 situation and its impacts, we remain committed to ensuring continued reliable and safe access to treatment.
MTPA knows patients count on us; therefore, we have built our supply chains so they are robust and resilient. We have ample supply of our treatment and do not anticipate an interruption of supply.
We have continued to maintain regular communication with infusion providers regarding safety procedures to combat COVID-19 and have worked with them to implement additional safety protocols and guidance to support patient care. As always, patients should speak with their doctors about any medical questions, including questions about COVID-19 or vaccinations against the pandemic.
The JourneyMate Support Program™ has a fully operational team in place which is available to provide information and guidance for doctors, patients and their caregivers regarding ordering and distribution support. To help address the potential impact on reimbursement approvals during the pandemic, MTPA also has implemented an electronic fax and eSign process* with doctors to enable signatures virtually, when possible.
For general information and to learn more about amyotrophic lateral sclerosis (ALS), a Resource Specialist is ready to help you find information and educational resources as you move forward on your journey with ALS. Your ALS Resource Specialist can be reached by calling toll-free 1-855-457-6968.
* As a reminder, all covered entities are obligated under the Health Insurance Portability and Accountability Act of 1996 (HIPAA) to have a business associate agreement (BAA) in place with any service provider that handles protected health information (PHI) on their behalf. This includes, among others, electronic data transmission services such as eSign and electronic fax services. Please refer to each service provider’s website for more information regarding BAAs and PHI.